The short answer
NAD+ is a coenzyme involved in cellular metabolism, not a peptide. Oral precursors such as nicotinamide riboside and clinician-led NAD+ services are different products and pathways. Raising a blood NAD+ marker does not by itself prove improved energy, slower ageing or a longer life.
NAD+, NR and peptides are different things
NAD+ stands for nicotinamide adenine dinucleotide. NR, or nicotinamide riboside, is a precursor that the body can use in NAD+ metabolism. Marketing often places NAD+, glutathione and copper peptides in one “cellular health” category, but that does not make the ingredients chemically or clinically interchangeable.
Ask which exact ingredient and formulation is being offered. Evidence about an oral precursor cannot automatically substantiate a claim about a different route, a combination kit or a product containing other ingredients.
What human studies can tell us
A randomised crossover trial in healthy middle-aged and older adults found that oral NR increased measures of NAD+ metabolism and was well tolerated over the study period. A separate eight-week trial found dose-dependent increases in whole-blood NAD+ with NR.
Those studies support specific statements about biomarkers and short-term tolerability under study conditions. They do not establish a universal anti-ageing effect. Another randomised trial in obese men did not find improved insulin sensitivity, illustrating why a plausible mechanism should not be equated with a clinical benefit.
Sources: Martens et al. (2018): placebo-controlled nicotinamide riboside trial · Conze et al. (2019): nicotinamide riboside safety and metabolism trial · Dollerup et al. (2018): nicotinamide riboside in obese men
What to check with an at-home NAD+ provider
NAD+ at Home is an example of a commercial provider presenting NAD+ and glutathione products and ongoing kits. Its website is useful for understanding what the provider offers and claims; it is not independent evidence that those claims are clinically established.
Before considering a clinical service, identify who assesses you, who supplies the product, what its regulatory status is and who responds to problems. Ask for evidence specific to the product and purpose you are considering, plus a written explanation of the total ongoing cost.
Sources: NAD+ at Home: provider website (commercial claims, not independent clinical evidence) · GPhC: staying safe when getting treatment online
Compare oral products by their actual formula
A supplement page should state the ingredient, amount per serving, other ingredients, allergens, directions and applicable restrictions. Do not assume that every substance marketed internationally is authorised for the same use in Great Britain or Northern Ireland.
A product’s lawful food status is also different from permission to claim it prevents or treats a disease. If a seller uses “longevity”, “detox” or “energy” language, ask what specific outcome was measured in people and whether it was measured with this product.
A practical consultation and comparison checklist
If tiredness is your main concern, discuss persistent symptoms with a healthcare professional rather than assuming a NAD+ deficiency. The symptom matters more than the trend, and an underlying cause may require a different approach.
- What improvement is realistic, and what evidence supports it for someone like me?
- What is known about risks, interactions and longer-term use?
- Who is clinically responsible, and how do I contact them?
- What monitoring or follow-up is included?
- Is the price for a starter kit, a refill or a continuing commitment?
- If halal status matters, what does the exact product certificate cover?
Common questions
Is NAD+ a peptide?
No. NAD+ is a coenzyme. Being listed in the same wellness category does not make it a peptide.
Does a higher NAD+ blood result mean I will feel better?
Not necessarily. A biomarker change and a meaningful improvement in symptoms are different outcomes.
Are oral NR and clinical NAD+ services equivalent?
No. They involve different products and routes. Evidence, suitability and regulatory requirements should be checked separately.
Sources & editorial note
AI-assisted editorial research prepared for Sanara Health on 8 September 2026. This page has not been clinically reviewed and does not provide a personal treatment recommendation. Product and regulatory information can change.
- Martens et al. (2018): placebo-controlled nicotinamide riboside trial
- Conze et al. (2019): nicotinamide riboside safety and metabolism trial
- Dollerup et al. (2018): nicotinamide riboside in obese men
- NAD+ at Home: provider website (commercial claims, not independent clinical evidence)
- GPhC: staying safe when getting treatment online
- MHRA: how products are classified as medicines